Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2018)
✉ Email this page to a colleague
AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2018)
Docket | ⤷ Sign Up | Date Filed | 2018-10-11 |
Court | District Court, D. Delaware | Date Terminated | 2019-11-03 |
Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
Jury Demand | Referred To | ||
Patents | 10,166,247; 7,759,328; 7,967,011; 8,143,239; 8,575,137 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in AstraZeneca AB v. Mylan Pharmaceuticals Inc.
Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2019-10-18 | 156 | Opinion - Memorandum Opinion | additional patent to the lawsuit, United States Patent No. 10,166,247 (the "#247 patent"). See…quot;#239 patent"), 8,575,137 (the "#137 patent"), and 7,967,011 (the #011 patent").…of infringing United States Patent Nos. 7,759,328 (the "#328 patent"), 8,143,239 (the 1 …Pharmaceuticals Inc. ("Mylan") and 3M Company for patent infringement. Before me is Mylan's motion to…Paragraph IV certifications against the asserted patents. D.I. 41, Ex. B. On August 15, 2018, the FDA sent | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |